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Summary Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We
show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results
encourage further research on the development of a clinically useful oral formulation of paclitaxel.
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Paclitaxel is an important new drug used in the treatment of a
variety ofhuman malignancies (Huizing et al, 1995; Rowinsky and
Donehower, 1995; McGuire et al, 1996). It is formulated in
Cremophor EL and ethanol (1:1, v/v; Taxol) and is currently
administered to patients by intravenous infusion. Oral administra-
tion of paclitaxel would offer several advantages, namely (a)
medication would no longerrequire a visit to the out-patient clinic,
(b) it may allow the achievement of lasting therapeutic plasma
levels and (c) it could prevent the adverse effects caused by the
vehicle substance Cremophor EL (Dorr, 1994). Thus far, however,
reports on the low oral bioavailability of paclitaxel in mice have
discouraged the development of an oral formulation (Eiseman
et al, 1994; Fujita et al, 1994). Recent experiments with mdrla
P-glycoprotein-deficient mice have demonstrated that this poor
uptake of orally administered paclitaxel results mainly from the
presence of P-glycoprotein in the intestines (Sparreboom et al,
1997), which is supported by in vitro experiments (Wacher et al,
1996). P-glycoprotein is a transmembrane protein that is present
in many normal tissues (Croop et al, 1989; Teeter et al, 1990;
Schinkel et al, 1994). This protein functions as an ATP-dependent
drug efflux pump and was initially discovered because of its
ability to confer multidrug resistance (MDR) in mammalian
tumour cells. The search for agents that may help to restore the
drug sensitivity of MDR tumour cells has led to the identification
and clinical testing of potent P-glycoprotein blockers, such as the
non-immunosuppressive cyclosporin analogue SDZ PSC 833
(Boesch et al, 1991; Keller et al, 1992; Fisher et al, 1996). We
hypothesized that concomitant oral administration of a P-glyco-
protein blocker might also increase the absorption oforally admin-
istered paclitaxel from the intestinal lumen (Sparreboom et al,
1997) and have tested this in mice using SDZ PSC 833.
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MATERIALS AND METHODS
SDZ PSC 833, kindly provided by Sandoz (Basel, Switzerland),
was dissolved in ethanol and Cremophor EL (1:1, v/v) to a final
concentration of 50 mg ml-'. The commercially available pacli-
taxel formulation [Taxol; 6 mg ml-' paclitaxel in Cremophor EL
and ethanol (1:1, v/v)] was obtained from Bristol-Myers Squibb
(Princeton, NJ, USA). These drug solutions were used to prepare a
mixed formulation containing 5 mg of SDZ PSC 833 and 1 mg of
paclitaxel per ml of Cremophor EL-ethanol-saline (2:2:1 1,
v/vlv). This mixture was administered to animals in the treatment
group at dose levels of50 mg kg-' (body weight) of SDZ PSC 833
and 10 mg kg-' (body weight) of paclitaxel. Animals in the
'control group' received 10 mg kg-' (body weight) of paclitaxel
alone, which was administered as a formulation containing mg
of paclitaxel per ml of Cremophor EL-ethanol-saline (2:2:11,
v/v/v). Female FVB mice (10-15 weeks of age) received 10 ,ul g-'
(body weight) ofdrug mixture directly into the stomach by using a
blunt-ended needle inserted via the oesophagus under light diethyl
ether anaesthesia. Blood samples were collected in heparinized
tubes from the retro-orbital venous plexus under diethyl ether
anaesthesia at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 20 h after drug
administration, using three to six animals per time point. The
blood was centrifuged (10 min, 2000g) and the plasma fraction
separated and stored at -20°C until analysis. The plasma concen-
tration of paclitaxel was determined by high-performance liquid
chromatography (Sparreboom et al, 1995). The area under the
plasma concentration-time curve (AUC) was calculated by the
linear trapezoidal rule without extrapolation to infinity, and the
standard error (s.e.) of the AUC was calculated with the law of
propagation of errors. The toxicity of the paclitaxel plus SDZ
PSC 833 regimen was checked in an additional set of four mice,
which were monitored for up to 2 months after a single drug
administration.
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Figure 1 Plasma concentration-time curves after oral administration of
paclitaxel to mice. Per kg of body weight, the mice received either 10 mg of
paclitaxel alone (0, control group) or in combination with 50 mg of SDZ PSC
833 (U). Symbols and error bars represent mean ± standard error. The
plasma concentration of paclitaxel in the control group at t= 12 h was below
25 ng ml-'
RESULTS
No significant loss of body weight or other macroscopic signs of
toxicity were observed in animals monitored for up to 2 months
after a single administration of paclitaxel plus SDZ PSC 833.
Combined treatment with SDZ PSC 833 resulted in a marked
increase in the AUCorai of paclitaxel from 735 ± 134 ng h ml-'
(mean ± s.e.) in the 'control group' to 8066 ± 819 ng h ml-l in the
group treated in combination with SDZ PSC 833 (Figure 1). The
maximum plasma concentration of paclitaxel was reached within
1-2 h after drug administration in both groups and was fivefold
higher in the group receiving the combined treatment with SDZ
PSC 833.
DISCUSSION
Our results show a strikingly increased AUCorai ofpaclitaxel in the
group treated in combination with SDZ PSC 833 compared with
the 'control' group. In order to obtain an estimate of the oral
bioavailabilities, we have used the data from our previous plasma
pharmacokinetic study in mice (Sparreboom et al, 1996). All
present experimental conditions were similar to these previous
experiments. AUCs obtained after intravenous administration of
paclitaxel in Cremophor EL-free formulations were used as
Cremophor EL causes non-linear pharmacokinetic behaviour of
paclitaxel (Sparreboom et al, 1996). Although the oral formulation
used in this study contained Cremophor EL, the systemic uptake of
this compound from the gastrointestinal tract was very low
(plasma levels <0.1%, v/v). After intravenous administration of 10
mg kg-' paclitaxel (formulated in dimethylacetamide or
Tween 80-ethanol) the AUC was approximately 3800 ng h ml-'
(Sparreboom et al, 1996). Treatment with 50 mg kg-' SDZ PSC
833 increased the 'bioavailability' (= AUCoral/AUCjv x 100%)
from 20% to 210%, suggesting that, apart from the effect of SDZ
PSC 833 on intestinal paclitaxel uptake by P-glycoprotein inhibi-
tion, the increased systemic exposure also results from the inter-
action of this agent with drug elimination pathways. This is also
supported by the fact that only a fivefold higher maximum plasma
concentration of paclitaxel was observed in mice treated with
SDZ PSC 833 compared with the 'control' group, whereas the
corresponding AUC ofpaclitaxel was increased by a factor of ten.
Various mechanisms may contribute to the decreased clearance,
e.g. both paclitaxel and cyclosporins are substrates for the
cytochrome P450 3A4 isozymes (Shet et al, 1993; Harris et al,
1994), which might have caused a metabolic interaction. The rela-
tive importance of these factors needs to be addressed in future
experiments.
In conclusion, the finding that the oral bioavailability of pacli-
taxel is substantially increased by the concomitant administration
of the P-glycoprotein blocker SDZ PSC 833 warrants further
research on the development ofa clinically useful oral formulation
ofpaclitaxel.
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